International Classification of Headache Disorders

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)

Retrieved on: 
Friday, June 24, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Review, Annual report, Migraine, PEARL, International Classification of Headache Disorders, Teva Pharmaceuticals, Headache, International Headache Society, IHS, Travel, Biosimilar, COVID-19, Failure, Health care, TASE, Silberstein, Pain, TEVA, Compliance, Cephalalgia, Knowledge Organization (journal), Woman, Teva, Investment, KPMG, Steiner, EU, Private Securities Litigation Reform Act, NYSE, Real, Observational study, Pain management, Forward-looking statement, Pharmaceutical industry, Silviculture, Aroma compound, Lipton, Ashina

AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled syringe or, in some countries, in a pre-filled pen.

Key Points: 
  • AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled syringe or, in some countries, in a pre-filled pen.
  • AJOVY can be administered either by a healthcare professional or at home by a patient or caregiver.
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century.
  • (v0.1) - The two year Pan-European Real World (PEARL) prospective, observational study of AJOVY (fremanezumab)
    2 KPMG, prepared for the European Migraine and Headache Alliance (EMHA).

electroCore Announces Publication in PharmacoEconomics Reiterating Economic Benefits of gammaCore for Cluster Headache Outlined by The National Institute for Health and Care Excellence (NICE) Medical Technologies Guidance

Retrieved on: 
Wednesday, August 4, 2021
Headaches, Symptoms and signs, Branches of biology, Medicine, Trigeminal autonomic cephalgia, Migraine, Cluster headache, Hemicrania continua, Headache, Medication overuse headache, International Classification of Headache Disorders

The paper is part of a series that provides insight into the development of UK National Institute for Health and Care Excellence (NICE) medical technologies guidance for new or innovative medical devices or diagnostics.

Key Points: 
  • The paper is part of a series that provides insight into the development of UK National Institute for Health and Care Excellence (NICE) medical technologies guidance for new or innovative medical devices or diagnostics.
  • The aim of the guidance is to support the adoption of clinically effective and cost-saving technologies in the UK National Health Service.
  • PharmacoEconomics reiterating the evidence supporting gammaCores effectiveness and economic benefit provides further support that gammaCore can play an important role in providing value-based therapy commented Iain Strickland, VP Global Sales and Strategy of electroCore.
  • gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

Migraine and Headache Awareness Month: gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Treats & Prevents Migraine and Cluster Headaches

Retrieved on: 
Tuesday, June 8, 2021
General Health, Health, Other Health, Medical devices, Headaches, Symptoms and signs, Medicine, Clinical medicine, Trigeminal autonomic cephalgia, Migraine, Medication overuse headache, Hemicrania continua, Cluster headache, Headache, International Classification of Headache Disorders, NIH classification of headaches, electroCore, Inc, gammaCore, ELECTROCORE, INC, GAMMACORE

Successful treatment with gammaCore may generate savings for patients and provide overall benefit by preventing attacks, reducing pain intensity and frequency.

Key Points: 
  • Successful treatment with gammaCore may generate savings for patients and provide overall benefit by preventing attacks, reducing pain intensity and frequency.
  • gammaCore may also help reduce medical costs for migraine including frequent doctors visits and pharmaceuticals or other treatments.
  • The companys current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.
  • gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

American Headache Society® to Hold 63rd Annual Scientific Meeting, June 3-6

Retrieved on: 
Thursday, June 3, 2021
Headaches, Medicine, Branches of biology, Health, Medical education, Accreditation Council for Continuing Medical Education, Headache, Continuing medical education, International Classification of Headache Disorders

"The American Headache Society's Virtual Annual Scientific Meeting continues to be the premiere venue for the dissemination of the latest research and scientific advances underlying the practice of Headache Medicine," said AHS Scientific Program Committee Chair, Dr. Amynah Pradhan, PhD.

Key Points: 
  • "The American Headache Society's Virtual Annual Scientific Meeting continues to be the premiere venue for the dissemination of the latest research and scientific advances underlying the practice of Headache Medicine," said AHS Scientific Program Committee Chair, Dr. Amynah Pradhan, PhD.
  • The American Headache Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  • The mission of the American Headache Society is to improve the care and lives of people living with headache disorders.
  • The American Headache Society (AHS) is a professional society of health care providers dedicated to the study and treatment of headache and face pain.

National Migraine and Headache Awareness Month Spotlights New Advances and Greater Understanding

Retrieved on: 
Tuesday, June 1, 2021
Human resources, University, Pharmaceutical, Training, Education, Managed care, Professional services, Mental health, Philanthropy, Fitness & Nutrition, Fund Raising, Foundation, Science, Nursing, Research, Health, Headaches, Migraine, Medicine, Branches of biology, Headache, Clinical medicine, International Classification of Headache Disorders, Anne MacGregor

The National Headache Foundation today released the following statement about National Migraine and Headache Awareness Month from Thomas Dabertin, MBA, executive director and chief executive officer of the National Headache Foundation:

Key Points: 
  • The National Headache Foundation today released the following statement about National Migraine and Headache Awareness Month from Thomas Dabertin, MBA, executive director and chief executive officer of the National Headache Foundation:
    More than 40 million people in the United States are living with migraine disease and headache disorders.
  • I had my first migraine in my teens, and it was one of the reasons that motivated me to lead the National Headache Foundation.
  • June is National Migraine and Headache Awareness Month; our time on the national stage, and I hope you will join me in finding a way to help yourself, a loved one, friend or co-worker better understand migraine disease and headache disorders.
  • The NHFs Annual Gala has raised millions of dollars to go towards migraine and headache research, education, awareness and advocacy.

Policy Discussion to Explore Chronic Headache Disorders and Toxic Exposure

Retrieved on: 
Thursday, March 18, 2021
Headaches, Symptoms and signs, Medicine, Branches of biology, Headache, Migraine, Burn pit, International Classification of Headache Disorders

WASHINGTON, March 18, 2021 /PRNewswire/ --On Tuesday, March 23, The Headache & Migraine Policy Forum and the Alliance for Headache Disorders Advocacy will host a policy panel discussion , "Chronic Headache Disorders & Toxic Exposure."

Key Points: 
  • WASHINGTON, March 18, 2021 /PRNewswire/ --On Tuesday, March 23, The Headache & Migraine Policy Forum and the Alliance for Headache Disorders Advocacy will host a policy panel discussion , "Chronic Headache Disorders & Toxic Exposure."
  • The event will explore the long-term impact of airborne hazards and burn pit exposure on 9/11 first responders and veterans.
  • Headache on the Hill includes more than 200 clinicians and patient advocates urging for more research funding for headache and migraine disorders.
  • STATEMENT FROM LINDSAY VIDENIEKS, EXECUTIVE DIRECTOR, THE HEADACHE & MIGRAINE POLICY FORUM:
    "For too long, veterans living with migraine disease and chronic headache disorders due to burn pit exposure have struggled to access adequate treatment for their disease.

Cluster Headache Syndrome (Cluster Headache) Pipeline Review, H2 2020 - Therapeutic Assessment of 9 Companies,, 3 Drug Profiles, Dormant Projects, Discontinued Products - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 9, 2020
Biotechnology, Pharmaceutical, Health, Headaches, Branches of biology, Medicine, Clinical medicine, Headache, Cluster headache, Cluster, Pipeline, International Classification of Headache Disorders

The "Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Cluster Headache Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

National Headache Foundation Virtual Golden Gala Raises More Than $140,000 to Benefit Headache Research and Celebrates 50 Years of Serving the Community

Retrieved on: 
Monday, October 26, 2020
Headaches, Branches of biology, Medicine, Clinical medicine, Headache, Migraine, International Classification of Headache Disorders

The Virtual Golden Gala raised more than $140,000 to further support NHF's mission of increasing headache awareness, supporting research serving as an educational resource, and advocating for anyone living with the disease.

Key Points: 
  • The Virtual Golden Gala raised more than $140,000 to further support NHF's mission of increasing headache awareness, supporting research serving as an educational resource, and advocating for anyone living with the disease.
  • More than 800 supporters from across the county participated in the virtual Golden Gala celebrating NHF's 50th anniversary as an organization.
  • For additional information on NHF's Virtual Golden Gala, please visit https://headaches.org/2020-gala/ and for more information on NHF's Headache Heroes, visit https://headaches.org/headache-heroes/ .
  • Founded in 1970, the National Headache Foundation is the oldest and largest foundation for individuals living with migraine disease and headache disorders.

electroCore, Inc. Announces Publication of a Voluntary ex-ante Transparency Tender Notice Award by NHS England to Fund Continued Use of gammaCore™ in England

Retrieved on: 
Monday, August 24, 2020
Health, Headaches, Medicine, Pain management, Clinical pharmacology, Health care quality, National Institute for Health and Care Excellence, Cluster headache, National Health Service, NHS England, Headache, International Classification of Headache Disorders

The award will provide further funding for the continued use of gammaCore for the treatment of cluster headache for patients who respond to the therapy.

Key Points: 
  • The award will provide further funding for the continued use of gammaCore for the treatment of cluster headache for patients who respond to the therapy.
  • gammaCore is rapidly becoming an established treatment option for clinicians and patients managing cluster headache in England.
  • In 2019, NICE published an evidence-based Medical Technology Guidance document recommending the use of gammaCore for cluster headache within NHS England.
  • In 2019, NICE published an evidence-based Medical Technology Guidance document recommending the use of gammaCore for cluster headache within NHS England.

electroCore to Participate in Three Upcoming Virtual Investor Conferences

Retrieved on: 
Thursday, July 9, 2020
Medicine, Clinical medicine, Organ systems, Headaches, Migraine, Pain management, Cluster headache, Vagus nerve, Headache, Prevention of migraines, International Classification of Headache Disorders

The companys initial targets are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

Key Points: 
  • The companys initial targets are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.
  • Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs.
  • When placed on a patients neck over the vagus nerve, gammaCore stimulates the nerves afferent fibers, which may lead to a reduction of pain in patients.
  • Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.